Selection of orlistat as a potential inhibitor for lipase from Candida species.

Related Articles

Selection of orlistat as a potential inhibitor for lipase from Candida species.

Bioinformation. 2011;7(3):125-9

Authors: Khedidja B, Abderrahman L

Abstract
Infections caused by Candida species manifest in a number of diseases, including candidemia, vulvovaginal candidiasis, endocarditis, and peritonitis. Candida species have been reported to possess lipolytic activity due to the secretion of lipolytic enzymes such as esterases, lipases and phospholipases. Extra-cellular hydrolytic enzymes seem to play an important role in Candida overgrowth. Candidiasis is commonly treated with antimycotics such as clotrimazole and nystatin. The antimycotics bind to a major component of the fungal cell membrane (ergosterol), forming pores that lead to death of the fungus. However, the secondary effects caused during such treatment have aroused a need to develop a treatment based on lipase inhibition. Nonetheless, no such lipase inhibitors for candidiasis treatment are currently available. Thus, we have performed a docking study with the natural inhibitor, orlistat or tetrahydrolipstatin. Our results have shown ten possible binding inhibitors to Candida rugosa lipase (CRL), out of which one possibility was selected, based on the weakest interatomic distance of 2.7 Å. Therefore, we propose the selection and design of a potential inhibitor candidate, orlistat for the treatment of candidiasis infections. However, this study has to be supported with in vitro and in vivo experiments to demonstrate the effectiveness of orlistat in lipase inhibition.

PMID: 22125382 [PubMed]

Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes

Journal of Antimicrobial Chemotherapy doi: 10.1093/jac/dkl237 Brunella Posteraro1, Maurizio Sanguinetti1*, Barbara Fiori1, Marilena La Sorda1, Teresa Spanu1,Dominique Sanglard2 and Giovanni Fadda1 istituto di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy; 2Institut de Microbiologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland Received 16 March 2006; returned 14 April 2006; revised 10 May 2006; accepted 12 …

Triazole-Polyene Antagonism in Experimental Invasive Pulmonary Aspergillosis: In Vitro and In Vivo Correlation

The Journal of Infectious Diseases 2006;194:1008-18 This article is in the public domain, and no copyright is claimed. 0022-1899/2006/19407-0019$15.00 Abstract Combination antifungal therapy is increasingly used in the treatment of invasive aspergillosis. Whether the interaction between amphotericin B and triazoles is antagonistic against invasive aspergillosis is a controversial issue that is not likely to be …

In Vitro Analyses, Animal Models, and 60 Clinical Cases of Invasive Aspergillus terreus Infection

Invasive aspergillosis (TA) is ihe most common filamentous fungal infection in immunocompromised patients (16, 51). However, not all Aspergillus species possess the same biologic attributes or even the same antifungal susceptibility patterns. Aspergillus fumigatus and A. flavus are the species most com- monly associated with TA (67, 99), and the frequency of TA caused by …

Actualidades en el manejo de las infecciones fúngicas en pacientes neutropénicos

INTRODUCCIÓN La forma como en la actualidad se practican la profilaxis y la terapéutica antifúngica empírica en pacientes neutropénicos deriva de las estrategias establecidas en las pasadas tres décadas para el manejo de las infecciones bacterianas en estos pacientes. Aunque el papel de la terapéutica antifúngica empírica en los pacientes con fiebre persistente después del …

Posaconazole: when and how? The clinician’s view

Aspasia Katragkou,1 Fotini Tsikopoulou,1 Emmanuel Roilides1 and Theoklis E. Zaoutis2,3 13rd Department of Pediatrics, Aristotle University Medical School, Hippokration Hospital, Thessaloniki, Greece, 2Center for Clinical Epidemiology and Biostatistics, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA and 3Division of Infectious Diseases, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA Summary Posaconazole …

Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience

Antimicrobial Agents and Chemotherapy, May 2007, p. 1616-1620 Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience Summary Aspergillus terreus, a less common pathogen, appears to be an emerging cause of infection at our institution, the Medical University Hospital of Innsbruck. Thus the epidemiology and outcome of A. terreus infections over …

A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study.

Crit Care Med. 2010 Aug;38(8):1651-64. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Kumar A, Safdar N, Kethireddy S, Chateau D. Source Medical Microbiology and Pharmacology/Therapeutics, University of Manitoba, Winnipeg, Manitoba, Canada. akumar61@yahoo.com Abstract OBJECTIVE: To …